SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (40)5/28/1999 9:53:00 PM
From: Miljenko Zuanic  Read Replies (2) of 447
 
<< Don't know. But, I wouldn't be surprised to see some hostile deals in the making.>>

Not that I am promoting acquisition or any similar speculation (far away from), but I will characterize current PFE-OSIP relation as *silence and friendly control* of R&D department. I guess hostile deals will not be necessary.

For instance lets look on last two news:
1. First PFE license to OSIP compounds (EGF/VEGF) for psoriasis.
2. OSIP clearly said that they will applied Anederm technology to develop topical formulation.
3. Two days later PFE is investing 50 M in Anederm (6 years).

SO, it seams that PFE is indirectly sponsoring psoriasis drug development, as a *gift* for long and productive collaboration.
I almost believe in this my words....

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext